35. Dong Y, Asch HL, Ying A, Asch BB (2002) Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells. Exp Cell Res 276: 328–336. 36. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, et al. (2009) Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 18: 1127–1133. 37. Shen Y, Jacobs JM, Camp DG, Fang R, Moore RJ, et al. (2004) Ultra-high- efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem 76: 1134–1144. 38. Smith RD, Anderson GA, Lipton MS, Pasa-Tolic´ L, Shen Y, et al. (2002) An accurate mass tag strategy for quantitative and high throughput proteome measurements. Proteomics 2: 513–523. Breast Cancer Degradomic View 39. Shen Y, Strittmatter EF, Zhang R, Metz TO, Moore RJ, et al. (2005) Making broad proteome protein measurements in 1-5 min using high-speed RPLC separations and high accuracy mass measurements. Anal Chem 77: 7763–7773. 40. Shen Y, Tolic´ N, Purvine SO, Smith RD (2010) Identification of disulfide bonds in protein proteolytic degradation products using de novo-protein unique sequence tags approach. J Proteome Res 9: 4053–4060. 41. Masselon C, Pasa-Tolic´ L, Tolic´ N, Anderson GA, Bogdanov B, et al. (2005) Targeted comparative proteomics by liquid chromatography-tandem Fourier ion cyclotron resonance mass spectrometry. Anal Chem 77: 400–406. 42. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4: 207–214. 43. Nesvizhskii A I, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646–4658. PLoS ONE | www.plosone.org 13 October 2010 | Volume 5 | Issue 10 | e13133